(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.34%) $82.73
(6.55%) $2.05
(0.01%) $2 347.50
(-0.35%) $27.44
(4.11%) $960.00
(-0.22%) $0.933
(-0.33%) $10.99
(-0.54%) $0.796
(1.55%) $93.30
Live Chart Being Loaded With Signals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...
Stats | |
---|---|
Dagens volum | 33.00 |
Gjennomsnittsvolum | 130.00 |
Markedsverdi | 5.16B |
Last Dividend | $0.500 ( 2023-08-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.35 |
ATR14 | $0 (0.00%) |
Hikma Pharmaceuticals PLC Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Hikma Pharmaceuticals PLC Økonomi
Annual | 2023 |
Omsetning: | $2.88B |
Bruttogevinst: | $1.39B (48.35 %) |
EPS: | $1.720 |
FY | 2023 |
Omsetning: | $2.88B |
Bruttogevinst: | $1.39B (48.35 %) |
EPS: | $1.720 |
FY | 2022 |
Omsetning: | $2.52B |
Bruttogevinst: | $1.24B (49.19 %) |
EPS: | $1.680 |
FY | 2021 |
Omsetning: | $2.55B |
Bruttogevinst: | $1.30B (50.96 %) |
EPS: | $3.57 |
Financial Reports:
No articles found.
Hikma Pharmaceuticals PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.380 (N/A) |
$0 (N/A) |
$0.740 (N/A) |
$0 (N/A) |
$0.500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.150 | 2012-04-18 |
Last Dividend | $0.500 | 2023-08-11 |
Next Dividend | $0 | N/A |
Payout Date | 2023-09-25 | |
Next Payout Date | N/A | |
# dividends | 24 | -- |
Total Paid Out | $8.89 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.65 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.96 | |
Div. Directional Score | 8.04 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MYBF | Ex Dividend Knight | 2023-10-04 | Quarterly | 0 | 0.00% | |
CODYY | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
SYIEY | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
HNHPF | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
ATLKY | Ex Dividend Knight | 2023-10-19 | Semi-Annually | 0 | 0.00% | |
OTGLY | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
DTCWY | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
TTDKF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
JMHLY | Ex Dividend Knight | 2023-08-16 | Semi-Annually | 0 | 0.00% | |
BNPQY | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0662 | 1.500 | 8.68 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0405 | 1.200 | 8.65 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0864 | 1.500 | -0.151 | -0.227 | [0.1 - 1] |
payoutRatioTTM | 0.723 | -1.000 | 2.77 | -2.77 | [0 - 1] |
currentRatioTTM | 1.568 | 0.800 | 7.16 | 5.73 | [1 - 3] |
quickRatioTTM | 0.890 | 0.800 | 9.47 | 7.58 | [0.8 - 2.5] |
cashRatioTTM | 0.153 | 1.500 | -0.261 | -0.391 | [0.2 - 2] |
debtRatioTTM | 0.254 | -1.500 | 5.76 | -8.64 | [0 - 0.6] |
interestCoverageTTM | 5.46 | 1.000 | 9.09 | 9.09 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.79 | 2.00 | 8.40 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 8.52 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.542 | -1.500 | 7.83 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.459 | 1.000 | 5.69 | 5.69 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.165 | 1.000 | 8.70 | 8.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.444 | 1.000 | 8.64 | 8.64 | [0.2 - 2] |
assetTurnoverTTM | 0.612 | 0.800 | 9.25 | 7.40 | [0.5 - 2] |
Total Score | 11.11 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.06 | 1.000 | 7.37 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0864 | 2.50 | -0.0971 | -0.227 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 9.01 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.05 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.79 | 2.00 | 8.40 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.723 | 1.500 | 2.77 | -2.77 | [0 - 1] |
pegRatioTTM | 1.954 | 1.500 | 0.306 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.185 | 1.000 | 7.88 | 0 | [0.1 - 0.5] |
Total Score | 4.96 |
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.